The DEFUSE 3 (Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3) trial is a prospective randomized phase III multicenter
controlled trial of patients with acute ischemic anterior circulation strokes due to large artery occlusion treated between six and 16 hours of stroke onset with endovascular thrombectomy therapy plus standard medical therapy versus standard medical therapy.